The $200 Billion Supply Test: IPO Normalization Meets SpaceX's Lockup Cliff

US IPO volumes are on pace to cross $200 billion this year, a new record^[1]. Goldman Sachs characterizes the surge as market normalization rather than speculative excess, pointing out that the roughly 60 US listings year-to-date remain well below the 25-year median of about 100 deals annually and far short of the nearly 400 companies that went public during the dot-com era^[2]. The current cycle, Goldman argues, is concentrated in a handful of large, high-quality issuers rather than a broad flood of speculative small deals — and public companies return roughly $1.6 trillion annually through dividends and buybacks, creating a powerful recycling mechanism that can absorb fresh supply^[2].

That thesis has held up reasonably well through July. The marquee event was SK hynix’s $26.5 billion Nasdaq listing on July 10 — the largest foreign-company IPO in US history, surpassing Alibaba’s 2014 record^[3]. The Korean memory-chip leader priced 177.9 million American depositary shares at $149 each, with the ADRs opening at $170, a 14 percent premium^[3]. The deal gave US investors direct, dollar-denominated access to the world’s leading maker of high-bandwidth memory (HBM) chips — the critical component in AI accelerators — and it signaled that the market can absorb a deal of that magnitude without cracking^[3].

On the smaller end, Scribe Therapeutics — a CRISPR gene-editing biotech co-founded by Jennifer Doudna — kicked off a second-half biotech IPO run on July 24, raising $128.7 million by pricing 8.6 million shares at $15, the high end of its $13–$15 range^[4]. The deal was upsized by 1.4 million shares and drew strong institutional demand, including a Sanofi private placement and Eli Lilly’s commitment to maintain its stake^[5]. The stock opened at $25 and closed its first session at $21.65, a 44 percent gain from the offer price^[5].

Meanwhile, 203 IPOs have priced on US markets so far in 2026 through July 20, a 6.8 percent increase over the same period in 2025^[4].

The SpaceX Lockup Cliff

All of this sets the stage for what may be the single largest market-structure event of the year: SpaceX’s lockup expiration.

SpaceX (NASDAQ: SPCX) went public on June 11 at $135 per share, raising what was reportedly the largest IPO in history^[6]. The stock initially traded above the offer but has since slipped below it, touching $128.97 on July 21 — roughly 36 percent below its all-time high^[7]. The decline has come amid operational setbacks, including an aborted Starship launch attempt, but the more durable pressure is structural: the public float is minuscule. Only about 555 million shares, or roughly 5 percent of the 13 billion total shares outstanding, are currently tradable^[7].

That float is about to expand dramatically. SpaceX is scheduled to report its first-ever quarterly earnings on August 4^[7]. Two days later, on August 6, the first major lockup tranche unlocks: approximately 911.5 million shares, representing 20 percent of locked-up stock^[7]. At the July 21 price near $129, that single tranche is valued at roughly $117 billion. An additional 10 percent tranche — about 455.8 million shares — could also unlock on the same date, but only if SPCX trades at least 30 percent above the $135 IPO price for at least 5 of the 10 consecutive trading days ending on the earnings release date^[7]. Given that the stock is currently trading below the IPO price, that conditional tranche appears unlikely to trigger.

A further 7 percent tranche, roughly 319 million shares valued at approximately $40.8 billion, is scheduled to unlock around August 21, with another 7 percent following on September 10^[7]. Elon Musk’s personal stake of 6.4 billion shares remains locked until June 2027 with no early release provisions^[7].

The scale is unprecedented. Roughly $123 billion in newly tradable shares — by the most widely cited estimate — is set to enter the market in early August^[6]. Historical data suggest that approximately 60 percent of stocks decline around lockup expiry as the increased supply of sellable shares pressures prices^[8]. But those historical comparisons involve deals a fraction of this size. No lockup expiration remotely close to $100 billion has occurred in modern market history.

The market’s capacity to absorb this supply is the open question. Index inclusion adds a complicating layer: S&P Dow Jones Indices has explicitly said it will not change its rules to fast-track mega-IPOs like SpaceX into the S&P 500^[9]. That means passive index funds tracking the benchmark will not be forced buyers on August 6. However, SpaceX has already been added to some broader total-market indexes, and competing index methodologies mean passive investors face unequal and potentially confusing exposure depending on which funds they hold^[9].

Alphabet’s Capital-Allocation Reversal

The supply picture extends beyond IPOs. Alphabet’s Q2 2026 earnings, released July 22, revealed a stark reversal: the company executed zero stock buybacks in the quarter, down from $13.2 billion in Q2 2025, and instead raised approximately $49.6 billion through a June equity issuance and $20.3 billion in senior notes^[10]. Long-term debt roughly doubled from about $46.5 billion to approximately $98 billion in a single quarter^[10].

Alphabet still holds approximately $240 billion in cash and marketable securities, so this is not a distressed balance sheet^[10]. But the signal is structural: the AI infrastructure buildout has grown large enough that even the most cash-generative company in tech is now raising external capital rather than returning it to shareholders^[10]. That shift turns Alphabet from a net buyer of its own stock into a net issuer — adding to the equity supply the market must absorb. If Microsoft, Meta, and Amazon follow the same logic over the next two to four quarters, as Alphabet’s move implies they might, the supply wave grows considerably larger^[10].

The Private Secondary Market: A Parallel Liquidity Story

While public IPO supply dominates headlines, the private secondary market hit its own record in the first half of 2026. Private asset secondary sales reached $121 billion in the first six months, an all-time high, with more than half the volume coming from manager-led transactions — primarily single-asset continuation funds^[11]. Private equity accounted for roughly two-thirds of those deals, with infrastructure at 16 percent and credit at 11 percent^[11].

Notably, software continuation funds dropped to just 10 percent of total secondary volume, down from 18 percent a year earlier, reflecting investor concern that AI could disrupt incumbent software companies^[11]. Evercore predicts the full year will set another annual record, with demand returning selectively for software assets where AI is viewed as a tailwind^[11].

IPO and Lockup Calendar: What’s Priced and What’s Unlocking

What to Watch Next

1. SpaceX’s August 4 earnings. The first quarterly report will set the tone for the lockup release two days later. If the stock is trading below the $135 IPO price at the time of the report — as it is now — the conditional 10 percent tranche (455.8 million shares) will not unlock, reducing but far from eliminating the supply shock. The 20 percent tranche unlocks regardless.

2. Actual selling pressure on August 6. Lockup expiration gives insiders the right to sell, not the obligation. How much of the 911.5 million unlocked shares actually hits the bid will determine whether this is a liquidity event or a non-event. Watch volume and the bid-ask spread in SPCX during the first trading days after the unlock.

3. Hyperscaler follow-through on Alphabet’s capital shift. If Microsoft, Meta, or Amazon announce similar equity raises or buyback pauses in their Q2 2026 reports, it confirms the supply wave is broadening beyond IPOs into the largest existing public companies.

4. IPO pricing quality in the back half. Goldman’s normalization thesis depends on issuers being large and fundamentally sound. The recent batch — SK hynix, Scribe, Csquare ($1.05B deal) — leans toward quality. Watch whether smaller, less-proven names begin flooding the calendar, which would test the “not a bubble” argument.

5. Private secondary market trajectory. With $121 billion already transacted in H1 2026 and Evercore projecting a full-year record, the private-to-public liquidity pipeline is functioning. A slowdown in secondary volume would signal that institutional LPs are pulling back — an early warning that the absorption capacity Goldman relies on may be tightening.

The base case remains that the market handles this supply. Corporate buybacks and dividends recycle roughly $1.6 trillion annually^[2], and the current IPO count of ~60 deals sits below the 25-year median^[2]. But the SpaceX lockup is a genuine unknown — there is no historical precedent for a $100 billion-plus unlock, and the thin initial float means the stock has never been tested at scale. The next two weeks will determine whether 2026’s IPO boom is a story about healthy normalization or the moment when supply finally overwhelmed demand.